Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

64
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
64
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

625
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
625
Model Approaches for Pharmacokinetic Data: Physiological Models01:15

Model Approaches for Pharmacokinetic Data: Physiological Models

36
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
36
Mechanistic Models: Overview of Compartment Models01:21

Mechanistic Models: Overview of Compartment Models

72
Mechanistic models, a category encompassing both physiological and compartmental modeling, differ from empirical models' approaches to incorporating known factors about the systems being modeled. Empirical models describe data with minimal assumptions, while mechanistic models aim to provide a robust description of available data by specifying assumptions and integrating known factors about the system. Compartmental analysis is a key example of a mechanistic model in pharmacokinetics and...
72
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

241
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
241
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

104
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
104

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Frequency Coding of Multisensory Integration in the Local Field Potentials of the Medial Pulvinar.

The European journal of neuroscience·2025
Same author

AI-Driven Applications in Clinical Pharmacology and Translational Science: Insights From the ASCPT 2024 AI Preconference.

Clinical and translational science·2025
Same author

Historical Use of Markov Model and Posterior Predictive Checks in Pharmacometrics.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Asia-inclusive drug development leveraging principles of ICH E5 and E17 guidelines: Case studies illustrating quantitative clinical pharmacology as a foundational enabler.

Clinical and translational science·2024
Same author

Explainable machine learning prediction of edema adverse events in patients treated with tepotinib.

Clinical and translational science·2024
Same author

Model-informed Evidence for Clinical Non-inferiority of Every-2-Weeks Versus Standard Weekly Dosing Schedule of Cetuximab in Metastatic Colorectal Cancer.

Clinical pharmacology and therapeutics·2024

Related Experiment Video

Updated: Jun 15, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K

Generative models for synthetic data generation: application to pharmacokinetic/pharmacodynamic data.

Yulun Jiang1, Alberto García-Durán2, Idris Bachali Losada2

  • 1School of Computer and Communication Science, Ecole Polytechnique Federale de Lausanne (EPFL), Lausanne, Switzerland.

Journal of Pharmacokinetics and Pharmacodynamics
|August 27, 2024
PubMed
Summary

Generating synthetic patient data using deep learning models like MLP cGAN can improve data access and availability for clinical research, especially for under-represented patient groups.

Keywords:
Deep learningGenerative methodsNeural networksSynthetic pharmacokinetic/Pharmacodynamic dataVirtual patients

More Related Videos

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.1K
MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data
07:17

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data

Published on: February 7, 2025

410

Related Experiment Videos

Last Updated: Jun 15, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.1K
MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data
07:17

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data

Published on: February 7, 2025

410

Area of Science:

  • Clinical Pharmacology
  • Biostatistics
  • Machine Learning

Background:

  • Synthetic patient data generation is crucial for enabling data access and augmenting datasets, particularly for under-represented populations.
  • Deep learning generative methods offer advanced solutions for creating realistic synthetic data.

Purpose of the Study:

  • To benchmark state-of-the-art deep learning generative methods for synthetic patient data generation.
  • To evaluate model performance across diverse clinical datasets and scenarios.

Main Methods:

  • Implemented and compared Multi-layer Perceptron Conditioning Generative Adversarial Neural Network (MLP cGAN), Time-series Generative Adversarial Networks (TimeGAN), and Probabilistic Autoregressive (PAR) models.
  • Evaluated performance using discriminative and predictive scores, statistical tests (Kolmogorov-Smirnov, Chi-square), and pharmacometrics-related metrics.

Main Results:

  • MLP cGAN demonstrated the best overall performance across most evaluated metrics.
  • The study confirmed the utility of synthetic data for augmenting and sharing proprietary clinical data.

Conclusions:

  • Deep learning generative models, particularly MLP cGAN, are effective for generating high-quality synthetic patient data.
  • Synthetic data generation holds significant potential for advancing clinical pharmacology research and data accessibility.